1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Ex-US FDA Official Sklamberg On Park Doctrine Limits, Data Integrity

 
• By Anju Ghangurde

Courts may increasingly find limits on how far Park Doctrine tool can be ‘pushed,’ Sklamberg says in wide-ranging interview with the Pink Sheet. Former US FDA deputy commissioner for global regulatory operations and policy, now with law firm Akin Gump, also shares his views on the US-EU MRA to recognize each other’s inspections and data integrity.

Compliance
SKLAMBERG EXPECTS COURTS TO WEIGH IN ON THE PARK DOCTRINE ISSUE

Howard Sklamberg, the former US FDA deputy commissioner for global regulatory operations and policy, was in Mumbai to address the India Pharmaceutical Forum 2018, an annual event where regulators, industry and other experts essentially discuss all things quality and compliance.Also see "Data Integrity Failures Undermine Trust That Can’t Easily Be Won Back, EMA Official Says" - Pink Sheet, 28 February, 2017.

In an interview with the Pink Sheet at the JW Marriott perched along the picturesque Juhu beach, Sklamberg, who is now with law firm Akin Gump as a partner in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By Sue Sutter

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.